Description of Research Expertise:
Application of high through-put technology to gain insights into the biology of human cancers, with special interest in GU cancers.
Priti Lal, Kosj Yamoah, Amy Ziober, Amy Walker, Wenting Zhou, Elaine Spangler, Charnita Zeigler-Johnson, Michael Feldman, Timothy R. Rebbeck.: Racial Differences in the Distribution of Prostate Tumor Biomarkers and Treatment Failure: The SCORE Study Clinical Cancer Research : 2015.
Kosj Yamoah, Michael Hiroshi Johnson, Voleak Choeurng, Kasra Yousefi, Zaid Haddad, Robert Benjamin Den, Priti Lal, Michael D Feldman, Adam Dicker, Eric A. Klein, Elai Davicioni, Timothy R. Rebbeck, Edward M. Schaeffer: A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer. Journal of Clinical oncology : 2015.
Kosj Yamoah, M.D., Ph.D.; Amy Walker, M.S.; Elaine Spangler, M.S.; Charnita M Zeigler-Johnson, M.D., Ph.D.; Bruce Malkowicz, M.D.; David I Lee, M.D.; Adam P Dicker, M.D., Ph.D.; Priti Lal, M.D.: African-American race is a predictor of seminal vesicle invasion following radical prostatectomy. Clinical Genitorurinary Cancer : 2014.
Priti Lal, MD: Chapter 39: Prostate.
Diagnostic molecular pathology. Diagnostic Molecular pathology, 2nd edition : 2015.
David J. Vaughn, MD,Wei-Ting Hwang, PhD,Priti Lal, MD,Mark Rosen, MD Maryann Gallagher, Peter J. O’Dwyer, MD: Phase II Trial of the CDK 4/6 Inhibitor Palbociclib in Patients with Retinoblastoma Protein Expressing Germ Cell Tumors Cancer : 2014.
Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean H. Hoffman-Censits, Katherine L. Nathanson, Priti Lal, Daniel A. Pryma, Scott Eliasof, Edward Graeme Garmey, Roger B. Cohen, Naomi B. Haas;: Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).
ASCO : 2014.
Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC: Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity.
Cancer Discov 4 (1): 53-60,2014.
Priti Lal, MD: Applications of OCT 4 in Diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.
Priti Lal, MD: Application of GATA 3 in diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.
Priti Lal, MD: Application of SALL4 in diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.